ABT

Abbott Laboratories 10-Q Summary: Period Ended June 30, 2026

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Abbott Laboratories for the three and six months ended June 30, 2026. The company operates four reportable segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. A defining event for this period was the completion of the acquisition of Exact Sciences Corporation on March 23, 2026, for approximately $20.6 billion, which significantly expanded Abbott's presence in the cancer diagnostics market.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13.0% in Q2 and 10.5% for the six months ended June 30, 2026. Organic growth (excluding foreign exchange) was 12.2% in Q2 and 8.2% for the six-month period, driven primarily by the Exact Sciences acquisition and growth in Medical Devices and Established Pharmaceutical Products.
• Profitability Decline: Net earnings decreased significantly (48% in Q2, 35% for 6M) compared to the prior year. This decline is attributed to increased interest expense from new debt, higher amortization of intangible assets from the acquisition, and increased SG&A and R&D expenses.
• Balance Sheet Shift: Long-term debt increased by approximately $19.7 billion due to the issuance of $20.0 billion in debt to fund the Exact Sciences acquisition. Cash and cash equivalents decreased by $3.4 billion, reflecting the cash portion of the acquisition, debt repayment, dividends, and share repurchases.
• Segment Performance: Diagnostic Products sales surged 42.3% in Q2 due to the inclusion of Exact Sciences. Medical Devices grew 9.0% (Q2) and 11.0% (6M). Nutritional Products declined 3.1% (Q2) and 4.5% (6M) due to lower volumes in adult and U.S. pediatric portfolios.

Outlook, Risks, and Unusual Items

• Acquisition Integration: The Exact Sciences acquisition added $1.0 billion in net sales for the first six months of 2026. Pro forma data suggests the acquisition would have added significant sales volume in the prior year but also increased interest and amortization expenses.
• Legal Proceedings: Abbott faces ongoing litigation regarding preterm infant formula and necrotizing enterocolitis (NEC). A $495 million verdict in a Missouri state court was affirmed by the Court of Appeals in May 2026; Abbott is seeking review by the Supreme Court of Missouri. Management estimates a potential loss range of $120 million to $530 million for all legal proceedings, with an accrued balance of $510 million.
• Tax Disputes: Abbott is contesting Statutory Notices of Deficiency (SNOD) from the IRS for tax years 2017–2020 totaling over $1 billion, related to income reallocation between U.S. and foreign entities. Additionally, a $413 million tax assessment by Malaysian authorities was upheld by the Penang High Court in October 2025, and Abbott has appealed to the Court of Appeals.
• Capital Allocation: The company repurchased approximately 11.6 million shares for $1.0 billion in the first six months of 2026. Dividends were increased to $0.63 per share in Q2 2026.

Investor Verification Checklist

• Debt Servicing: Verify the impact of the new $20 billion debt issuance on future interest coverage ratios and cash flow availability.
• Acquisition Synergies: Monitor the integration progress of Exact Sciences and the realization of projected synergies versus the increased amortization and integration costs.
• Legal Exposure: Track the outcome of the Supreme Court of Missouri review regarding the NEC verdict and the status of the Malaysian tax appeal.
• Organic Growth: Assess the sustainability of organic growth in Medical Devices and Established Pharmaceuticals, excluding the one-time impact of the Exact Sciences acquisition.
• Margin Pressure: Evaluate whether gross margins can recover from the 52.5% level given the mix shift and higher intangible amortization.